Valuation: OliX Pharmaceuticals, Inc

Market Cap 3,394B 2.19B 1.92B 1.77B 1.65B 3.11B 208B 3.17B 21.27B 8.24B 102B 8.22B 8.04B 355B P/E 2026 *
-108x
P/E 2027 * -111x
Enterprise Value 3,394B 2.19B 1.92B 1.77B 1.65B 3.11B 208B 3.17B 21.27B 8.24B 102B 8.22B 8.04B 355B EV / Sales 2026 *
424x
EV / Sales 2027 * 309x
Free-Float
82.92%
Yield 2026 *
-
Yield 2027 * -
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
06-01 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-01 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-08 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
21/03/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2024 CI
10/02/25 Lilly, South Korean Drug Maker Partnering to Commercialize Prospective Liver Disease Treatment MT
1 day+7.33%
1 week+20.66%
Current month+7.33%
1 month-3.36%
3 months-16.71%
6 months+18.95%
Current year+18.95%
1 week 133,200
Extreme 133200
179,400
1 month 112,000
Extreme 112000
179,400
Current year 111,800
Extreme 111800
217,000
1 year 35,000
Extreme 35000
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 59 28/03/2022
Director/Board Member 53 29/03/2021
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap.
28/02/25Fiscal year

Director

30,000 0.1625%
28/02/25Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%+20.66%+340.05%+881.78% 2.19B
+1.46%+2.99%+72.12%+130.45% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+0.82%+5.23%+39.74%-30.16% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +2.29%+8.11%+80.65%+222.02% 23.81B
Weighted average by Cap. +1.45%+6.71%+58.90%+139.07%

Financials

2026 *2027 *
Net sales 8B 5.16M 4.53M 4.17M 3.89M 7.33M 491M 7.48M 50.15M 19.43M 241M 19.37M 18.95M 838M 11B 7.09M 6.23M 5.73M 5.34M 10.08M 674M 10.28M 68.95M 26.72M 331M 26.64M 26.06M 1.15B
Net income -31B -19.99M -17.55M -16.16M -15.06M -28.39M -1.9B -28.97M -194M -75.29M -933M -75.06M -73.44M -3.25B -30B -19.35M -16.99M -15.64M -14.57M -27.48M -1.84B -28.04M -188M -72.86M -903M -72.64M -71.07M -3.14B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
01/07/26 ₩167,000.00 +7.33% 518,166
30/06/26 ₩155,600.00 -6.94% 401,264
29/06/26 ₩167,200.00 +24.22% 844,686
26/06/26 ₩134,600.00 -4.34% 300,629
25/06/26 ₩140,700.00 +1.66% 290,354
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock